• HighLife Clarity Treatment of Severe Mitral Regurgitation

  NCT06683729

  Not yet recruitingInterventionalNot ApplicableUpdated Sep 15, 2025
• HighLife™ Transcatheter Mitral Valve Replacement System Study

  NCT02974881

  CompletedInterventionalNot ApplicableUpdated Oct 3, 2024
• An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System

  NCT04029337

  RecruitingInterventionalNot ApplicableUpdated Mar 17, 2025
• Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk

  NCT04029363

  RecruitingInterventionalNot ApplicableUpdated Sep 15, 2025
• Feasibility Study of Patients With Severe MR Treated With the Cardiovalve TMVR System

  NCT03714412

  WithdrawnInterventionalNot ApplicableUpdated May 7, 2026
• Safety and Efficacy of the HighLife Transcatherter Mitral Valve Replacement System in Patients With Moderate-severe or Severe Mitral Regurgitation in China

  NCT05610566

  RecruitingInterventionalNot ApplicableUpdated Nov 9, 2022

ClinicalTrials.gov ID

NCT04888247

Lead Sponsor

HighLife SASINDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

30Estimated

Last Update Posted

Oct 3, 2024Actual

Start Date

Jul 1, 2021Actual

Primary Completion Date

Dec 1, 2025Estimated

Completion Date

Feb 1, 2031Estimated

Official Title

HighLife TSMVR Feasibility Study of the Open Cell CLARITY Valve in Patients With Moderate-severe or Severe MR, High Surgical Risk and With a High Risk for Left Ventricular Outflow Tract Obstruction (LVOTO)

Brief Summary

Feasibility, safety and performance of the HighLife CLARITY TSMV and its delivery system

Detailed Description

Study to assess the feasibility, safety, and performance of the HighLife CLARITY TSMV, and its deliver systems, in NYHA Class ≥ II-IV patients with moderate-severe or severe mitral regurgitation who are at high risk for surgical treatment according to the local multidisciplinary Heart Team decision, and who are at high risk for potential LVOT obstruction(LVOTO).

• Mitral Regurgitation

• CLARITY

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Age ≥ 18 years
2. Moderate-severe or severe mitral regurgitation (≥ 3+)
3. Patient has New York Heart Association (NYHA) Functional Class II, III or ambulatory IV
4. Patient is under guideline directed medical therapy for at least one month, as reviewed and confirmed by the local multidisciplinary Heart Team
5. Patient is high-risk for open-heart surgery based on the assessment of the multidisciplinary Heart Team using standard scoring systems and consideration of co-morbidities, frailty, and disability
6. Patient meets the anatomical criteria for HighLife valve
7. Patient is willing to participate in the study and provides signed informed consent
8. Patients with a high risk for LVOTO

Exclusion Criteria:

1. Any stroke/TIA within 30 days

2. Severe symptomatic carotid stenosis (> 70% by non-invasive imaging)

3. Active infections requiring antibiotic therapy

4. Active ulcer or gastro-intestinal bleeding in the past 3 months

5. History of bleeding diathesis, coagulopathy or refusal of future blood transfusion

6. Patients in whom TEE is not feasible

7. Patients who are pregnant or lactating, or plan to get pregnant in the next 12 months.

8. Patient is unable to comply with the follow-up schedule and assessments

9. Participation in another clinical investigation at the time of inclusion

10. Patient has known allergies to the device components or contrast medium

11. Patient cannot tolerate anticoagulation or antiplatelet therapy

12. Patients with a life expectancy of less than 12 months due to non-cardiac conditions

13. Patient had permanent pacemaker, or similar device with implantable cardiac leads (i.e. resynchronization therapy) within the last 3 months

    -

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

HighLife SASINDUSTRY

eric.vanbelle@chu-lille.fr